Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, discusses his highlights from the BTOG 2021 meeting, commenting on the combination of immuno-oncology agents and targeted agents for the treatment of patients with lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
Colin Lindsay, BSc, MBChB, MRCP, PhD, has participated in an advisory role for Amgen and cbpartners; has participated in clinical trials with Amgen, Apollomics, BI, Mirati Therapeutics, Revolution Medicines and Roche; and has participated in a review paper coordinated by Amgen.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.